90221-50-4

Basic information

• Product Name: N-(2-BROMO-5-NITROPHENYL)ACETAMIDE
• Synonyms: N-(2-BROMO-5-NITROPHENYL)ACETAMIDE;RTSTZQRSWJGBNU-UHFFFAOYSA-N
• CAS NO: 90221-50-4
• Molecular Formula: C₈H₇BrN₂O₃
• Molecular Weight: 259.06
• Mol File: 90221-50-4.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(2-BROMO-5-NITROPHENYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-BROMO-5-NITROPHENYL)ACETAMIDE(90221-50-4)
• EPA Substance Registry System: N-(2-BROMO-5-NITROPHENYL)ACETAMIDE(90221-50-4)

Safety Data

• Hazardous Substances Data: 90221-50-4(Hazardous Substances Data)

Upstream product

• 54582-26-2 α-6-bromo-3-nitro-acetophenone oxime 
• 64-19-7 acetic acid 
• 99-09-2 3-nitro-aniline 
• 60-29-7 diethyl ether 
• 10026-13-8 phosphorus pentachloride 
• 10403-47-1 2-bromo 5-nitroaniline 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 

Downstream Products

• 21762-74-3 6-nitro-3,4-dihydro-3-oxo-2H(1,4)benzothiazine 
• 2941-66-4 2-methyl-5-nitrobenzothiazole 
• 453562-67-9 N-(2-bromo-5-nitrophenyl)-N-(2-methylprop-2-enyl)-acetamide 
• 32046-51-8 2-methyl-5-nitro-1,3-benzoxazole 
• 68867-15-2 N-(2-methyl-1,3-benzothiazol-5-yl)acetamide 
• 453562-71-5 1-(6-amino-3,3-dimethyl-2,3-dihydroindol-1-yl)ethanone 
• 38463-33-1 2-Methylthiazolochinolin 
• 13382-43-9 2-methyl-5-aminobenzothiazole 
• 116529-42-1 2-bromo-4,5-dinitro-aniline 
• 453562-68-0 1-(3,3-dimethyl-6-nitro-2,3-dihydro-indol-1-yl)-ethanone 

Relevant articles and documents

Synthesis of dibenzothiophene, dibenzofuran and carbazole donor-acceptor chromophores

We present efficient synthetic protocols for functionalizing dibenzothiophene, dibenzofuran, and carbazole with hydroxy and nitro or cyano groups. The synthesis of these donor-acceptor chromophores is based on a key Suzuki-Miyaura coupling using an approp

PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells

The use of nitroreductases (NTR) that catalyze the reduction of nitro compounds by using NAD(P)H in GDEPT (Gene-directed enzyme prodrug therapy) studies which minimize toxicity at healthy cells and increases concentration of drugs at cancer cells is remarkable. Discovery of new prodrug/NTR combinations is necessary to be an alternative to known prodrug candidates such as CB1954, SN23862, PR-104A. For this aim, nitro containing aromatic amides (A1-A23) were designed, synthesized, performed in silico ADMET and molecular docking techniques in this study. Prodrug candidates were studied on reduction potentials with Ssap-NtrB by HPLC system. Also, cyototoxic properties and prodrug ability of these amides were investigated using different cancer cell lines such as Hep3B and PC3. As a result of theoretical and biological studies, combinations of A5, A6 and A20 with Ssap-NtrB can be suggested as potential prodrugs/enzyme combinations at NTR based cancer therapy compared with CB1954/NfsB.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.